Mimetas BV participating in €325m cancer...Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands. more ➔
Hansa Biopharmas imlifidase advances to...The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharmas imlifidase in anti-GBM disease. more ➔
GSK acquires Sierra Oncology for 1.9bnGlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis. more ➔
Scientists print 3D cancer modelA 3D tumour model developed by scientists enables drug screening in metastases more ➔
Affimed prices public offering to finance...Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m. more ➔
GeNeuro finds biologic against post-COVID... Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases. more ➔
Catalent swallows VMIC LtdCatalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction. more ➔
AXA launches €440 m private equity healt...AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector. more ➔
Bayer Leaps to invests €1.3bn externallyGerman Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’. more ➔
Avantium closes financing for FDCA plantAvantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF. more ➔
